Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036341 (
schizophrenia
)
60,220
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Accumulating evidence suggests that both homocysteine metabolism and monoaminergic neurotransmitter systems are important in
schizophrenia
pathology. We hypothesized that the gene PNPO (pyridoxine 5'-phosphatase oxidase gene) might be a candidate for susceptibility to
schizophrenia
because PNPO encodes
pyridoxamine 5'-phosphate oxidase
(
EC 1.4.3.5
), a rate-limiting enzyme in pyridoxal 5'-phosphate (PLP, vitamin B(6)) synthesis. PLP is a metabolically-active form of vitamin B(6) and thus, is required as a co-factor for enzymes involved in both homocysteine metabolism and synthesis of neurotransmitters such as catecholamine. We examined 8 single nucleotide polymorphisms (SNPs) in PNPO and its 5'-flanking regions in 359
schizophrenia
patients and 582 control subjects. Four marker regions of PNPO showed significant levels of allelic associations with
schizophrenia
(the highest was rs2325751, P=0.004). In addition, the haplotype case-control study revealed a significant association (permutation P<0.00001) between PNPO and
schizophrenia
. These findings suggest that variations in PNPO may contribute to overall genetic risk for
schizophrenia
in the Japanese population.
...
PMID:Association between PNPO and schizophrenia in the Japanese population. 1785 Oct 41